MicroPulse Transscleral Cyclophotocoagulation for Early to Moderate Glaucoma: A Case Series of 11 Eyes with One-Year Follow-Up and Literature Review

Purpose: To assess the efficacy and safety of MicroPulse Transscleral Cyclophotocoagulation (MP-TSCPC) in Chinese patients with early to moderate glaucoma over a one-year follow-up. Patients and Methods: This retrospective case series included 11 eyes of 11 consecutive Chinese patients with early to moderate glaucoma who underwent MP-TSCPC between November 2023 and March 2024. All patients were aged 18-80 years, had a baseline intraocular pressure (IOP) ≥ 21 mmHg, and completed at least 12 months of follow-up. MP-TSCPC was performed using an Iridex Cyclo G6 laser with standardized settings (2000 mW power, 31.3% duty cycle, 160 seconds total). Changes in IOP, the number of anti-glaucoma medications, best-corrected visual acuity (BCVA), surgical success rates, and complications were recorded. Results: At 12 months, mean IOP decreased significantly from 28.64±12.18 mmHg to 18.09±7.70 mmHg (P